Aclarion Inc (ACON)vsAstraZeneca PLC (AZN)
ACON
Aclarion Inc
$3.26
-3.26%
HEALTHCARE · Cap: $8.03M
AZN
AstraZeneca PLC
$187.37
+1.17%
HEALTHCARE · Cap: $287.11B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 77563612% more annual revenue ($58.74B vs $75,730). AZN leads profitability with a 17.4% profit margin vs 0.0%. AZN earns a higher WallStSmart Score of 64/100 (C+).
ACON
Avoid33
out of 100
Grade: F
AZN
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ACON.
Margin of Safety
+4.1%
Fair Value
$214.51
Current Price
$187.37
$27.14 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Revenue surging 80.6% year-over-year
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.4B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Expensive relative to growth rate
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : ACON
The strongest argument for ACON centers on Price/Book, Revenue Growth. Revenue growth of 80.6% demonstrates continued momentum.
Bull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bear Case : ACON
The primary concerns for ACON are EPS Growth, Market Cap, Profit Margin.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Revenue Growth.
Key Dynamics to Monitor
ACON profiles as a hypergrowth stock while AZN is a value play — different risk/reward profiles.
ACON carries more volatility with a beta of 1.14 — expect wider price swings.
ACON is growing revenue faster at 80.6% — sustainability is the question.
AZN generates stronger free cash flow (1.4B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 33/100), backed by strong 17.4% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Aclarion Inc
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
Aclarion Inc (ACON) is a leading healthcare technology company dedicated to enhancing patient care through non-invasive diagnostic solutions leveraging advanced data analytics and machine learning. The firm specializes in innovative imaging techniques that streamline treatment pathways for musculoskeletal conditions, equipping healthcare professionals with actionable insights to improve clinical outcomes while reducing costs. Positioned at the forefront of the digital health revolution, Aclarion is well-equipped to address the rising demand for effective diagnostic tools, significantly contributing to the evolution of healthcare delivery in a dynamic environment. With a strong focus on advancing patient management, Aclarion is set to redefine standards in the healthcare sector.
Visit Website →AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Compare with Other HEALTH INFORMATION SERVICES Stocks
Want to dig deeper into these stocks?